Paper6213633
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Harris AL and 5 others. J Clin Endocrinol Metab, 1982. Cited by 87 papers, by iCite.
Cite this record
ConductScience Library. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. Papers, record 6213633. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6213633
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminoglutethimide | Major topic |
| Breast Neoplasms | Major topic |
| Adult | |
| Androstenedione | |
| Dehydroepiandrosterone | |
| Dehydroepiandrosterone Sulfate | |
| Drug Therapy, Combination | |
| Estradiol | |
| Female | |
| Humans | |
| Hydrocortisone | |
| Hydroxyprogesterones | |
| Menopause | |
| Menstruation | |
| Middle Aged |
Source PubMed
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 87 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 10874521 | Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. | Drugs Aging | 2000 | https://conductscience.org/library/papers/10874521 | PubMed |
| 8595151 | Aromatase inhibitors--where are we now? | Br J Cancer | 1996 | https://conductscience.org/library/papers/8595151 | PubMed |
| 8431370 | Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8431370 | PubMed |
| 7949205 | First generation aromatase inhibitors--aminoglutethimide and testololactone. | Breast Cancer Res Treat | 1994 | https://conductscience.org/library/papers/7949205 | PubMed |
| 6684948 | Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6684948 | PubMed |
| 6238616 | Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6238616 | PubMed |
| 6221746 | Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6221746 | PubMed |
| 3912013 | Could aminoglutethimide replace adrenalectomy? | Breast Cancer Res Treat | 1985 | https://conductscience.org/library/papers/3912013 | PubMed |
| 3778807 | Role of aminoglutethimide in male breast cancer. | Br J Cancer | 1986 | https://conductscience.org/library/papers/3778807 | PubMed |
| 3730249 | Agranulocytosis associated with aminoglutethimide: pharmacological and marrow studies. | Br J Cancer | 1986 | https://conductscience.org/library/papers/3730249 | PubMed |
| 3436111 | Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. | Clin Pharmacokinet | 1987 | https://conductscience.org/library/papers/3436111 | PubMed |
| 3358910 | The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients. | Br J Cancer | 1988 | https://conductscience.org/library/papers/3358910 | PubMed |
| 3048976 | Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. | Drugs | 1988 | https://conductscience.org/library/papers/3048976 | PubMed |
| 2952154 | The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients. | Br J Cancer | 1987 | https://conductscience.org/library/papers/2952154 | PubMed |
| 2933050 | A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. | Br J Cancer | 1985 | https://conductscience.org/library/papers/2933050 | PubMed |
| 2570093 | Endocrine therapy of metastatic breast cancer. | J Endocrinol Invest | 1989 | https://conductscience.org/library/papers/2570093 | PubMed |
| 2508735 | Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects. | Br J Cancer | 1989 | https://conductscience.org/library/papers/2508735 | PubMed |
| 2145964 | The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. | Br J Cancer | 1990 | https://conductscience.org/library/papers/2145964 | PubMed |
| 2123133 | Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2123133 | PubMed |
| 1931611 | Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. | Br J Cancer | 1991 | https://conductscience.org/library/papers/1931611 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6213633
GET https://conductscience.org/api/papers/v1/6213633/cited_by?page=2